NEW YORK (GenomeWeb) – Blood-based cancer detection firm Thrive Earlier Detection announced its launch today, supported by a $110 million financing round.

The Cambridge, Massachusetts-based firm plans to commercialize a circulating tumor DNA and protein testing method initially developed at Johns Hopkins University and currently being validated in a 10,000-person trial with Pennsylvania's Gesinger Health system.